Ethic Inc’s Coherus Oncology CHRS Stock Holding History

Ethic Inc’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,397	Closed	-$15.7K	–	1179
2024 Q4	$15.7K	Buy	+11,397	New	+$12.8K	﹤0.01%	1142

Other funds holding CHRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ethic Inc's CHRS Position: Q1 2025 in Review

Ethic Inc sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 11,397 shares — an estimated $15.7K sold.

Ethic Inc first reported a position in CHRS in Q4 2024 and held it in 1 quarter. The position peaked at $15.7K in Q4 2024. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

Ethic Inc reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
Ethic Inc sold 11,397 Coherus Oncology shares in Q1 2025, an estimated $15.7K.
Ethic Inc first reported a position in Coherus Oncology in Q4 2024 and held it in 1 quarter.
Ethic Inc's Coherus Oncology position peaked at $15.7K in Q4 2024.
117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Ethic Inc's 13F filing for Q1 2025, filed 13 May 2025.